Academy Exchange

We have a Hep C  patient who completed his 12 week regimen of Epclusa with a viral load dropping from 561,000 to 464 during treatment, and at 3 months post his VL is now 4,666,000. Genotype 3. He is compliant, has no risk of re-exposure. Non-cirrhotic, no jaundice, no ascites- overall healthy. No co-infections. Abd US- mild hepatomegaly, no focal discrete mass. 

Ns5a testing recently completed with PROBABLE aclatasvir and velpatasvir drug resistance. His insurance is requiring Vosevi for re-treatment.  We are recommending Mavyret, especially due to probable resistance.  Is Vosevi a truly viable option/ recommended? Any guidance appreciated. 

What was his previous genotype?

We have a Hep C  patient who completed his 12 week regimen of Epclusa with a viral load dropping from 561,000 to 464 during treatment, and at 3 months post his VL is now 4,666,000. Genotype 3. He is compliant, has no risk of re-exposure. Non-cirrhotic, no jaundice, no ascites- overall healthy. No co-infections. Abd US- mild hepatomegaly, no focal discrete mass. 

Ns5a testing recently completed with PROBABLE aclatasvir and velpatasvir drug resistance. His insurance is requiring Vosevi for re-treatment.  We are recommending Mavyret, especially due to probable resistance.  Is Vosevi a truly viable option/ recommended? Any guidance appreciated.